Almirall, S.A. (0O9B.IL)
| Previous close | 8.51 |
| Open | 8.48 |
| Bid | 8.37 x 0 |
| Ask | 8.74 x 0 |
| Day's range | 8.48 - 8.61 |
| 52-week range | 7.20 - 10.08 |
| Volume | |
| Avg. volume | 109,271 |
| Market cap | 1.956B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.18 (2.03%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
- Business Wire
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
BARCELONA, Spain, November 17, 2023--Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. Almirall will first start the commercial launch in Germany. The company will continue
- Business Wire
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
BARCELONA, Spain & VANCOUVER, Wash., November 14, 2023--Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise w
- Business Wire
Almirall’s Nine-month 2023 Results:
BARCELONA, Spain, November 09, 2023--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.
